Overview

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.
Phase:
Phase 1
Details
Lead Sponsor:
EpicentRx, Inc.